Tvardi Therapeutics (TVRD) Cash from Operations: 2012-2024
Historic Cash from Operations for Tvardi Therapeutics (TVRD) over the last 13 years, with Dec 2024 value amounting to -$60.9 million.
- Tvardi Therapeutics' Cash from Operations rose 13.46% to -$11.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$54.8 million, marking a year-over-year decrease of 15.72%. This contributed to the annual value of -$60.9 million for FY2024, which is 33.84% up from last year.
- According to the latest figures from FY2024, Tvardi Therapeutics' Cash from Operations is -$60.9 million, which was up 33.84% from -$92.1 million recorded in FY2023.
- In the past 5 years, Tvardi Therapeutics' Cash from Operations registered a high of -$5.5 million during FY2020, and its lowest value of -$92.1 million during FY2023.
- For the 3-year period, Tvardi Therapeutics' Cash from Operations averaged around -$77.2 million, with its median value being -$78.7 million (2022).
- Its Cash from Operations has fluctuated over the past 5 years, first soared by 94.98% in 2020, then slumped by 995.08% in 2021.
- Over the past 5 years, Tvardi Therapeutics' Cash from Operations (Yearly) stood at -$5.5 million in 2020, then plummeted by 995.08% to -$60.1 million in 2021, then plummeted by 31.03% to -$78.7 million in 2022, then decreased by 16.95% to -$92.1 million in 2023, then skyrocketed by 33.84% to -$60.9 million in 2024.